Tuberculosis and Respiratory Diseases

The Korean Academy of Tuberculosis and Respiratory Diseases (대한결핵및호흡기학회)
권호 표지
DOI QR코드

DOI QR Code

Safety and Effectiveness of Indacaterol in Chronic Obstructive Pulmonary Disease Patients in South Korea

  • Yum, Ho-Kee (Department of Internal Medicine, Inje University Seoul Paik Hospital, Inje University College of Medicine) ;
  • Kim, Hak-Ryul (Department of Internal Medicine, Wonkwang University School of Medicine) ;
  • Chang, Yoon Soo (Department of Internal Medicine, Yonsei University College of Medicine) ;
  • Shin, Kyeong-Cheol (Division of Pulmonology and Allergy, Department of Internal Medicine, Regional Center for Respiratory Disease, Yeungnam University College of Medicine) ;
  • Kim, Song (Novartis Korea Ltd.) ;
  • Oh, Yeon-Mok (Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine)
  • Received : 2016.02.23
  • Accepted : 2016.06.22
  • Published : 2017.01.31
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Inhaled indacaterol (Onbrez Breezhaler), a long-acting ${\beta}_2$-agonist, is approved in over 100 countries, including South Korea, as a once-daily bronchodilator for maintenance and treatment of chronic obstructive pulmonary disease (COPD). Here, we present an interim analysis of a post-marketing surveillance study conducted to evaluate the real-world safety and effectiveness of indacaterol in the Korean population. Methods: This was an open-label, observational, prospective study in which COPD patients, who were newly prescribed with indacaterol (150 or $300{\mu}g$), were evaluated for 12 or 24 weeks. Safety was assessed based on the incidence rates of adverse events (AEs) and serious adverse events (SAEs). Effectiveness was evaluated based on physician's assessment by considering changes in symptoms and lung function, if the values of forced expiratory volume in 1 second were available. Results: Safety data were analyzed in 1,016 patients of the 1,043 enrolled COPD patients receiving indacaterol, and 784 patients were included for the effectiveness analysis. AEs were reported in 228 (22.44%) patients, while 98 (9.65%) patients reported SAEs. The COPD condition improved in 348 patients (44.4%), while the condition was maintained in 396 patients (50.5%), and only 40 patients (5.1%) exhibited worsening of ailment as compared with baseline. During the treatment period, 90 patients were hospitalized while nine patients died. All deaths were assessed to be not related to the study drug by the investigator. Conclusion: In real-life clinical practice in South Korea, indacaterol was well tolerated in COPD patients, and can be regarded as an effective option for their maintenance treatment.

Keywords

References

  1. Gold Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease [Internet]. Gold Initiative for Chronic Obstructive Lung Disease; 2016 [cited 2016 Jan 12]. Available from: http://www.goldcopd.org.
  2. Park H, Jung SY, Lee K, Bae WK, Lee K, Han JS, et al. Prevalence of chronic obstructive lung disease in Korea using data from the fifth Korea national health and nutrition examination survey. Korean J Fam Med 2015;36:128-34. https://doi.org/10.4082/kjfm.2015.36.3.128
  3. Murphy L, Rennard S, Donohue J, Molimard M, Dahl R, Beeh KM, et al. Turning a molecule into a medicine: the development of indacaterol as a novel once-daily bronchodilator treatment for patients with COPD. Drugs 2014;74:1635-57. https://doi.org/10.1007/s40265-014-0284-7
  4. McKeage K. Indacaterol: a review of its use as maintenance therapy in patients with chronic obstructive pulmonary disease. Drugs 2012;72:543-63. https://doi.org/10.2165/11208490-000000000-00000
  5. Patalano F, Banerji D, D'Andrea P, Fogel R, Altman P, Colthorpe P. Addressing unmet needs in the treatment of COPD. Eur Respir Rev 2014;23:333-44. https://doi.org/10.1183/09059180.00004014
  6. Geake JB, Dabscheck EJ, Wood-Baker R, Cates CJ. Indacaterol, a once-daily beta2-agonist, versus twice-daily beta(2)-agonists or placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2015;1:CD010139.
  7. Kinoshita M, Lee SH, Hang LW, Ichinose M, Hosoe M, Okino N, et al. Efficacy and safety of indacaterol 150 and 300 microg in chronic obstructive pulmonary disease patients from six Asian areas including Japan: a 12-week, placebo-controlled study. Respirology 2012;17:379-89. https://doi.org/10.1111/j.1440-1843.2011.02107.x
  8. To Y, Kinoshita M, Lee SH, Hang LW, Ichinose M, Fukuchi Y, et al. Assessing efficacy of indacaterol in moderate and severe COPD patients: a 12-week study in an Asian population. Respir Med 2012;106:1715-21. https://doi.org/10.1016/j.rmed.2012.09.002
  9. Donohue JF, Singh D, Kornmann O, Lawrence D, Lassen C, Kramer B. Safety of indacaterol in the treatment of patients with COPD. Int J Chron Obstruct Pulmon Dis 2011;6:477-92.
  10. Chapman KR, Rennard SI, Dogra A, Owen R, Lassen C, Kramer B, et al. Long-term safety and efficacy of indacaterol, a long-acting beta(2)-agonist, in subjects with COPD: a randomized, placebo-controlled study. Chest 2011;140:68-75. https://doi.org/10.1378/chest.10-1830
  11. Ohno T, Wada S, Hanada S, Sawaguchi H, Muraki M, Tohda Y. Efficacy of indacaterol on quality of life and pulmonary function in patients with COPD and inhaler device preferences. Int J Chron Obstruct Pulmon Dis 2014;9:107-14.
  12. Juvelekian G, El-Sorougi W, Pothirat C, Yunus F, De Guia T, Kuo HP, et al. A real-world evaluation of indacaterol and other bronchodilators in COPD: the INFLOW study. Int J Chron Obstruct Pulmon Dis 2015;10:2109-20.

Cited by

  1. Indacaterol : Orthostatic hypotension: case report vol.1645, pp.1, 2017, https://doi.org/10.1007/s40278-017-28242-x
  2. The safety of indacaterol for the treatment of COPD vol.17, pp.6, 2017, https://doi.org/10.1080/14740338.2018.1472233
  3. Pharmacotherapy for chronic obstructive pulmonary disease vol.61, pp.9, 2017, https://doi.org/10.5124/jkma.2018.61.9.545
  4. SRSF6-regulated alternative splicing that promotes tumour progression offers a therapy target for colorectal cancer vol.68, pp.1, 2019, https://doi.org/10.1136/gutjnl-2017-314983
  5. Fixed-Dose Combinations of Long-Acting Bronchodilators for the Management of COPD: Global and Asian Perspectives vol.36, pp.3, 2017, https://doi.org/10.1007/s12325-019-0893-3
  6. Real-world Safety and Efficacy of Indacaterol Maleate in Patients with Chronic Obstructive Pulmonary Disease: Evidence from the Long-term Post-marketing Surveillance in Japan vol.60, pp.15, 2017, https://doi.org/10.2169/internalmedicine.5571-20
  7. Targeting Splicing Factor SRSF6 for Cancer Therapy vol.9, pp.None, 2021, https://doi.org/10.3389/fcell.2021.780023